Meningococcal Polysaccharide Serogroups A, C, W-135 And Y Conjugate Vaccine
Noted VaccinesRestrictedNot applicable line
Prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135, and Y in children aged 12 months, adolescents aged 14–19 years, and medically at-risk individuals aged ≥12 months (those with asplenia, complement deficiency, or undergoing eculizumab treatment).
1
Submissions
2020–20
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Mar 2023 Noted Prevention of meningococcal disease no PSD
Access path
- Nov 2020Recommended
vs Nimenrix (meningococcal serogroup A, C, W-135 and Y tetanus…
- PBS listing · Restricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
The PBAC recommended that meningococcal serogroup A, C, W-135 and Y Polysaccharide Tetanus Toxoid Conjugate (MenACWY-TT, MenQuadfi) vaccine be a designated vaccine for the purposes of the National Health Act 1953, for the prevention of IMD caused by Neisseria meningitidis serogroups A, C, W135, and Y, for children aged 12 months, adolescents aged 14 to 19 years and at-risk individuals who are 12 months of age and older and are currently eligible for …PSD · Nov 2020
The PBAC considered the nomination of Nimenrix as the main comparator for the three populations (children 12 months of age, adolescents aged 14 to 19 years of age and medically at risk individuals over 12 months of age) and Menveo as a ‘near market’ comparator for the adolescent population was appropriate. The PBAC noted Menveo was listed on the NIP for the adolescent population during evaluation of the submission.PSD · Nov 2020
Economic analysis
The submission presented a cost-minimisation analysis versus the currently listed MenACWY vaccine, Nimenrix.PSD · Nov 2020
The submission stated that the sponsor would match the revealed NNP of Nimenrix if MenQuadfi was recommended for listing on the NIP. The submission proposed a proxy price of $'''''''''''' for MenQuadfi and Nimenrix.PSD · Nov 2020
Clinical claim
The submission described MenQuadfi as non-inferior in terms of effectiveness and safety compared with Nimenrix in children aged approximately 12 months and in adolescents aged 14-19 years. 13PSD · Nov 2020
Children 12 months: The submission claimed that MenQuadfi was non-inferior to Nimenrix in terms of immunogenicity and safety. The ATAGI considered this claim was reasonable. However, none of the trials collected clinical efficacy data in terms of cases of MenACWY avoided. Immunogenicity does not necessarily correlate to efficacy of a vaccine to prevent a disease.PSD · Nov 2020
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated. Submission based on cost-minimisation versus Nimenrix.
The submission requested a listing based on a cost-minimisation analysis versus Nimenrix. PSD · 2020
Decision context
PopulationChildren aged 12 months; adolescents aged 14–19 years; medically at-risk subjects aged ≥12 months with congenital or acquired asplenia, complement deficiency, or undergoing eculizumab treatment.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2020 | Recommended | Nimenrix (meningococcal serogroup A, C, W-135 and Y tetanus toxoid conjugate vaccine) | — | RCT · Seroresponse rate (hSBA antibody titre ≥1:8) |
Similar precedents
Meningococcal Polysaccharide Conjugate Vaccine Serogroups A, C, W-135 And Y84%Meningococcal (Groups A, C, W-135 And Y) Oligosaccharide Crm197 Conjugate Vaccine82%Meningococcal Group B Vaccine, Multicomponent (4cmenb)74%Meningococcal Group B Vaccine (Recombinant, Adsorbed)72%Pneumococcal Polysaccharide Conjugate Vaccine, 13-Valent72%Meningococcal Group B Vaccine (4cmenb)71%Pneumococcal Conjugate Vaccine, 20-Valent69%Pneumococcal Conjugate Vaccine, 15-Valent68%